霍利表示,海蒂·奥弗顿博士承诺将于2027年3月前完成审查并在同年9月前采取行动
作者:路易斯·卡西阿诺 福克斯新闻
发布时间:美国东部时间2026年11月20日下午3:38 | 更新时间:美国东部时间2026年11月20日下午4:00
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/image.jpg
支持生命的组织称,因奥弗顿未就堕胎药问题作出承诺,导致其FDA提名未获通过
苏珊·B·安东尼支持生命组织法律战略高级副总裁埃里克·巴普蒂斯特解释了该组织为何反对海蒂·奥弗顿的FDA提名,原因是特朗普政府未就恢复堕胎药的面对面配药要求、及处理该机构米非司酮安全审查的相关问题作出承诺。
NEW 您现在可以收听福克斯新闻的文章了!
【福克斯独家首发】 密苏里州共和党参议员、卫生、教育、劳工与养老金委员会(HELP)成员乔希·霍利的办公室于周五告知福克斯新闻数字版,曾任美国食品药品监督管理局(FDA)局长提名人的海蒂·奥弗顿博士,已承诺为堕胎药米非司酮的安全审查制定具有约束力的时间节点和明确参数。
霍利作为参议院卫生、教育、劳工与养老金委员会成员,数月来一直向联邦卫生官员施压,要求其对这项已被推迟的评估工作作出问责。
“这些是支持生命事业的重大胜利,将有助于确保开展全面审查,并可能恢复拜登政府取消的堕胎药关键保护措施,”霍利在给福克斯新闻数字版的声明中表示。
“我希望FDA能兑现这些承诺;作为HELP委员会成员,任何未来的FDA局长提名人都必须承诺完成这项工作,才能获得我的支持。”
【特朗普将提名海蒂·奥弗顿博士担任下一任FDA局长】
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/hawley-abortion-pill.jpg
密苏里州共和党参议员、参议院卫生、教育、劳工与养老金委员会成员乔希·霍利表示,他已从FDA局长提名人海蒂·奥弗顿博士手中获得承诺,将为堕胎药米非司酮的安全审查制定具有约束力的时间节点和数据参数。(图片来源:Evelyn Hockstein/路透社;Tom Williams-Pool/盖蒂图片社)
白宫在参议院委员会投票的前一天撤回了海蒂·奥弗顿的提名。2026年8月,当特朗普选中这名医生兼白宫顾问接替5月辞职的马蒂·马卡里时,曾称赞奥弗顿是“摇滚明星”。
根据霍利办公室的消息,特朗普政府已承诺在2027年3月前完成全面的米非司酮安全审查,并要求FDA在不晚于2027年9月前根据审查结果实施监管改革。
更新后的安全协议将适用于品牌名米非司酮及其仿制药。
【联邦上诉法院裁定堕胎药可邮寄,裁决在全国范围内有效】
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/josh-hawley-ai.jpg
2026年9月24日,密苏里州共和党参议员乔希·霍利抵达华盛顿特区出席参议院卫生、教育、劳工与养老金委员会的提名听证会。(图片来源:Daniel Heuer/Bloomberg via Getty Images)
霍利的办公室指出,潜在的这项审查将分析拜登政府解除限制前后的医疗补助数据和商业可用数据。
自2023年以来,对该药物的联邦监管一直受到持续质疑,当时拜登政府取消了要求医生必须面对面问诊、且必须面对面配药的规定。
【霍利敦促司法部就堕胎药制造商的安全问题展开调查】
尽管FDA官员此前承诺在2025年发布相关研究,但该机构的审查多次被推迟,批评者担心其排除了关键数据。
“FDA已解释其打算使用合适的数据和合格专家尽快完成正在进行的审查,遵循证据,并在法律允许的最大范围内公布科学依据和结果,”奥弗顿在提名被撤回前,于参议院委员会提名问卷中写道。
【白宫在参议院小组投票前夕撤回特朗普的FDA提名人海蒂·奥弗顿】
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/fda.jpg
2015年10月14日,马里兰州银泉市的美国食品药品监督管理局园区。(图片来源:AP Photo/Andrew Harnik,文件照片)
【点击下载福克斯新闻应用程序】
“如果获得确认,我将支持尽快完成这项工作,同时维护科学审查的完整性,”她补充道。
今年3月,霍利敦促共和党同僚支持他提出的禁止米非司酮的法案。
“现在证据已经很明确,”他当时表示。“米非司酮几乎总会导致胎儿死亡,但对女性来说也存在严重危险。生产这种药物的制药公司心知肚明,却继续从该药物近乎不受监管的分销中获利,且大多不受追责。国会不能再忽视这些危险了。”
路易斯·卡西阿诺是福克斯新闻数字版的记者。可将新闻线索发送至louis.casiano@fox.com。
EXCLUSIVE: Trump’s former FDA nominee vowed new abortion pill safety review after pressure from Sen Hawley
Hawley says Dr Heidi Overton pledged to finalize the review by March 2027 and act by September 2027
By Louis Casiano Fox News
Published November 20, 2026 3:38pm EST | Updated November 20, 2026 4:00pm EST
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/image.jpg
Pro-life group says lack of abortion drug commitments drove opposition to Overton’s failed FDA bid
Erik Baptist, senior vice president of legal strategy at Susan B. Anthony Pro-Life America, explains why the group opposed Heidi Overton’s FDA confirmation without commitments from the Trump administration to restore in-person dispensing requirements for abortion drugs and address concerns about the agency’s mifepristone safety study.
NEW You can now listen to Fox News articles!
FIRST ON FOX: Dr. Heidi Overton, a former nominee for Food and Drug Administration (FDA) commissioner, had committed to establishing a binding timeline and clear parameters for a safety study on the abortion medication mifepristone, the office of Sen. Josh Hawley, R-Mo., told Fox News Digital Friday.
Hawley, a member of the Senate Health, Education, Labor and Pensions (HELP) Committee, has spent months pressing federal health officials for accountability over the delayed assessment.
“These are major pro-life wins that help ensure a robust study and the potential reinstatement of critical safeguards on the abortion drug that President Biden stripped away,” Hawley said in a statement to Fox News Digital.
“I will expect that the FDA will live up to these promises, and as a member of the HELP Committee, any future FDA commissioner nominee must commit to carrying this through in order to earn my support.”
TRUMP TO NOMINATE DR HEIDI OVERTON AS NEXT FDA COMMISSIONER
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/hawley-abortion-pill.jpg
Sen. Josh Hawley, R-Mo., who sits on the Senate Health, Education, Labor and Pensions Committee, said he had secured commitments from Dr. Heidi Overton, nominee for Food and Drug Administration commissioner, to establish a binding timeline and data parameters for a safety study on the abortion medication mifepristone.(Evelyn Hockstein/Reuters; Tom Williams-Pool/Getty Images)
The White House pulled Heidi Overton’s nomination one day before a Senate committee vote. President Donald Trump hailed Overton as a “ROCKSTAR” in August when he picked the physician and White House advisor to succeed Marty Makary, who resigned in May.
According to Hawley’s office, the Trump administration had pledged to finalize a comprehensive mifepristone safety study by March 2027, with the FDA committing to enact regulatory changes supported by the findings no later than September 2027.
Updated safety protocols would have applied to both brand-name mifepristone and its generic equivalents.
FEDERAL APPEALS COURT BLOCKS MAILING OF ABORTION PILLS IN RULING WITH NATIONWIDE EFFECT
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/josh-hawley-ai.jpg
Sen. Josh Hawley, R-Mo., arrives for a Senate Health, Education, Labor, and Pensions Committee confirmation hearing in Washington, D.C., Sept. 24, 2026.(Daniel Heuer/Bloomberg via Getty Images)
Hawley’s office noted that the potential study will analyze Medicaid and commercially available data spanning periods before and after the Biden administration lifted restrictions.
Federal oversight of the medication has drawn sustained scrutiny since 2023, when the Biden administration eliminated requirements mandating in-person doctor visits and in-person dispensing.
HAWLEY URGES DOJ PROBE INTO ABORTION PILL MAKER OVER SAFETY CONCERNS
The FDA’s review has faced repeated postponements despite earlier pledges by officials to release a study in 2025 amid concerns from critics that the agency was excluding critical data.
“FDA has explained its intention to quickly complete its ongoing review using appropriate data and qualified experts, follow the evidence, and make the scientific basis and results public to the greatest extent permitted by law,” Overton wrote in her Senate committee confirmation questionnaire prior to her nomination being pulled.
WHITE HOUSE PULLS TRUMP’S FDA PICK HEIDI OVERTON ON EVE OF SENATE PANEL VOTE
https://news-multimedia-1393112320.cos.ap-guangzhou.myqcloud.com/fda.jpg
The Food and Drug Administration campus in Silver Spring, Md., Oct. 14, 2015.(AP Photo/Andrew Harnik, File)
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“If confirmed, I would support completing that work as expeditiously as practicable while preserving the integrity of the scientific review,” she added.
In March, Hawley urged fellow Republicans to back his legislation to ban mifepristone.
“The evidence is now clear,” he said at the time. “Mifepristone is almost always fatal to the unborn child, but it is also significantly dangerous for women. The drug companies that make this drug know this but continue to profit from the drug’s nearly unregulated distribution, largely insulated from liability. Congress can no longer ignore these dangers.”
Louis Casiano is a reporter for Fox News Digital. Story tips can be sent to louis.casiano@fox.com.
发表回复